Company intelligence / Profile preview

Althera Laboratories

Morristown, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Althera Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of cardiovascular therapies. The company's lead product is Roszet, a fixed-dose combination of rosuvastatin and ezetimibe, which was approved by the FDA in 2021 for the treatment of hyperlipidemia. Althera aims to improve patient outcomes by providing convenient combination treatments that address high cholesterol through multiple mechanisms of action. The company operates primarily in the United States and targets the large market for lipid-lowering medications.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Althera Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Althera Laboratories.

Explore the full profile